These findings suggest that in CML patients, the preferential substrate recognition of LASP1 by Lyn kinase could serve as a new read-out in patients with beginning TKI resistance, given that these patients show higher Lyn kinase activity as a characteristic of emerging BCR-ABL-independent resistance [44,45]. The gene discussed is LASP1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.